期刊
NEURO-ONCOLOGY
卷 25, 期 8, 页码 1381-1394出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noad059
关键词
deep venous thrombosis; glioblastoma; glioma; pulmonary embolism; podoplanin; tissue factor; venous thromboembolism
Patients with diffuse glioma have a high risk of developing venous thromboembolism (VTE), especially those with glioblastoma. Efforts are being made to identify biomarkers that can predict the increased risk of VTE, but there is currently no established prophylactic treatment. Therapeutic anticoagulation with LMWH or DOACs is recommended for VTE treatment, but the risk of intracranial hemorrhage in glioblastoma patients makes anticoagulation challenging. Investigational anticoagulants that prevent thrombosis without impairing hemostasis may offer a better therapeutic option.
Patients with diffuse glioma are at high risk of developing venous thromboembolism (VTE) over the course of the disease, with up to 30% incidence in patients with glioblastoma (GBM) and a lower but nonnegligible risk in lower-grade gliomas. Recent and ongoing efforts to identify clinical and laboratory biomarkers of patients at increased risk offer promise, but to date, there is no proven role for prophylaxis outside of the perioperative period. Emerging data suggest a higher risk of VTE in patients with isocitrate dehydrogenase (IDH) wild-type glioma and the potential mechanistic role of IDH mutation in the suppression of production of the procoagulants tissue factor and podoplanin. According to published guidelines, therapeutic anticoagulation with low molecular weight heparin (LMWH) or alternatively, direct oral anticoagulants (DOACs) in patients without increased risk of gastrointestinal or genitourinary bleeding is recommended for VTE treatment. Due to the elevated risk of intracranial hemorrhage (ICH) in GBM, anticoagulation treatment remains challenging and at times fraught. There are conflicting data on the risk of ICH with LMWH in patients with glioma; small retrospective studies suggest DOACs may convey lower ICH risk than LMWH. Investigational anticoagulants that prevent thrombosis without impairing hemostasis, such as factor XI inhibitors, may carry a better therapeutic index and are expected to enter clinical trials for cancer-associated thrombosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据